KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Average (2016 - 2025)

Historic Equity Average for Halozyme Therapeutics (HALO) over the last 15 years, with Q4 2025 value amounting to $276.4 million.

  • Halozyme Therapeutics' Equity Average fell 3230.71% to $276.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $276.4 million, marking a year-over-year decrease of 3230.71%. This contributed to the annual value of $206.3 million for FY2025, which is 781.76% down from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Equity Average is $276.4 million, which was down 3230.71% from $418.3 million recorded in Q3 2025.
  • Halozyme Therapeutics' Equity Average's 5-year high stood at $423.0 million during Q1 2025, with a 5-year trough of $93.7 million in Q2 2021.
  • Moreover, its 5-year median value for Equity Average was $214.7 million (2021), whereas its average is $236.9 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Equity Average plummeted by 6081.09% in 2023, and later surged by 22340.95% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' Equity Average (Quarter) stood at $239.3 million in 2021, then plummeted by 44.26% to $133.4 million in 2022, then grew by 24.81% to $166.5 million in 2023, then skyrocketed by 145.21% to $408.3 million in 2024, then crashed by 32.31% to $276.4 million in 2025.
  • Its last three reported values are $276.4 million in Q4 2025, $418.3 million for Q3 2025, and $407.5 million during Q2 2025.